Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) stock fell -1.73% on Monday to $17.06 against a previous-day closing price of $17.36. With 0.62 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.8 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $17.68 whereas the lowest price it dropped to was $16.76. The 52-week range on SNDX shows that it touched its highest point at $29.86 and its lowest point at $16.76 during that stretch. It currently has a 1-year price target of $36.33. Beta for the stock currently stands at 1.14.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SNDX was down-trending over the past week, with a drop of -1.73%, but this was down by -4.96% over a month. Three-month performance dropped to -18.57% while six-month performance fell -23.33%. The stock lost -30.57% in the past year, while it has lost -32.97% so far this year. A look at the trailing 12-month EPS for SNDX yields -2.44 with Next year EPS estimates of -2.78. For the next quarter, that number is -0.79. This implies an EPS growth rate of -628.70% for this year and 5.40% for next year.
Float and Shares Shorts:
At present, 69.64 million SNDX shares are outstanding with a float of 65.74 million shares on hand for trading. On Aug 30, 2023, short shares totaled 6.96 million, which was 10.01% higher than short shares on Jul 30, 2023. In addition to Mr. Michael A. Metzger M.B.A. as the firm’s CEO & Director, Mr. Keith Alan Goldan CPA serves as its CFO, Treasurer & Chief Accounting Officer.
Institutional Ownership:
Other institutions hold 55.15% of SNDX, in contrast to 34.65% held by mutual funds. Shares owned by individuals account for 10.05%. As the largest shareholder in SNDX with 10.71% of the stake, Wellington Management Co. LLP holds 7,444,184 shares worth 7,444,184. A second-largest stockholder of SNDX, BlackRock Fund Advisors, holds 4,481,077 shares, controlling over 6.45% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in SNDX, holding 4,154,061 shares or 5.98% stake. With a 4.45% stake in SNDX, the Vanguard Health Care Fund is the largest stakeholder. A total of 3,092,082 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 4.17% of SNDX stock, is the second-largest Mutual Fund holder. It holds 2,894,438 shares valued at 53.58 million. Vanguard Total Stock Market ETF holds 2.88% of the stake in SNDX, owning 2,002,391 shares worth 37.06 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, SNDX reported revenue of $0.00 and operating income of -$37.72M. The EBITDA in the recently reported quarter was -$36.87M and diluted EPS was -$0.62.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SNDX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With SNDX analysts setting a high price target of $42.00 and a low target of $32.00, the average target price over the next 12 months is $36.50. Based on these targets, SNDX could surge 146.19% to reach the target high and rise by 87.57% to reach the target low. Reaching the average price target will result in a growth of 113.95% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded SNDX stock several times over the past three months with 5 Buys and 5 Sells. In these transactions, 188,710 shares were bought while 188,710 shares were sold. The number of buy transactions has increased to 40 while that of sell transactions has risen to 35 over the past year. The total number of shares bought during that period was 803,660 while 692,237 shares were sold.
